| Stereochemistry | ABSOLUTE |
| Molecular Formula | C36H41ClN8O4S |
| Molecular Weight | 717.28 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@@H](C)N1N=CN(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OC[C@@H]5CO[C@](CSC6=NN=CN6C)(O5)C7=CC=C(Cl)C=C7)C=C4
InChI
InChIKey=HQSRVYUCBOCBLY-XOOFNSLWSA-N
InChI=1S/C36H41ClN8O4S/c1-4-26(2)45-35(46)44(25-39-45)31-11-9-29(10-12-31)42-17-19-43(20-18-42)30-13-15-32(16-14-30)47-21-33-22-48-36(49-33,27-5-7-28(37)8-6-27)23-50-34-40-38-24-41(34)3/h5-16,24-26,33H,4,17-23H2,1-3H3/t26-,33-,36-/m1/s1
| Molecular Formula | C36H41ClN8O4S |
| Molecular Weight | 717.28 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Mitratapide is a potent inhibitor of the microsomal triglyceride transfer protein used for the treatment of obesity in dogs. The drug was developed by Janssen Pharmaceutica and is chemically related to the antifungal drugs such as itraconazole which were also developed by Janssen. Administration of mitratapide to dogs results in reduced uptake of dietary lipids, dose dependent decreases in serum cholesterol and triglyceride and an increased presence of triglyceride containing droplets in enterocytes. Mitratapide also has a slight appetite decreasing effect that is claimed to be associated with its mode of action. Vomiting, diarrhoea or softened stools may occur during treatment. In most cases, these effects are mild and transient.
